Target intelligence / Profile preview

T-cell receptor restricted by HLA-A*24:02 (HLA-A*24:02-restricted TCR)

Target
HLA-A*24:02-restricted TCR
Molecular classification
Receptor, T-cell receptor, MHC Class I-restricted receptor
01

Overview

The HLA-A*24:02-restricted cytotoxic T lymphocyte receptor (TCR) is a heterodimeric protein complex on the surface of CD8+ T cells that specifically recognizes peptide antigens presented by the HLA-A*24:02 allele of the Major Histocompatibility Complex (MHC) Class I [1, 3]. This recognition is a cornerstone of the cellular immune response, enabling T cells to detect and destroy cells presenting non-self or mutated peptides, such as those from viruses or tumors [3]. HLA-A*24:02 is highly prevalent in East Asian populations, particularly in Japan, where it is found in approximately 60% of the population, making it a primary focus for the development of TCR-engineered T-cell (TCR-T) therapies [1, 4]. In these applications, T cells are modified to express a TCR that targets specific antigens like WT1, NY-ESO-1, or MAGE-A4 when presented by HLA-A*24:02 [2, 4]. Binding of the TCR to the peptide-HLA complex triggers a signaling cascade that leads to the release of cytotoxic granules, such as perforin and granzymes, resulting in the apoptosis of the target cell [3].

Other names
HLA-A*24:02-restricted TCRA24-restricted TCRHLA-A24-restricted T-cell receptorHLA-A*24:02-restricted cytotoxic T lymphocyte receptor
02

Mechanism of action

TCR-engineered T cells express this receptor to recognize and bind specific peptide-HLA-A*24:02 complexes on target cells, inducing T-cell activation and cytotoxic effector functions.

03

Biological functions

Immune responseAntigen recognitionCell-mediated cytotoxicitySignal transduction
04

Disease associations

CancerInfection
05

Safety considerations

Cytokine release syndrome (CRS)On-target off-tumor toxicityOff-target cross-reactivityHLA downregulation
06

Interacting drugs

TBI-1301

2 more in the full profile.

07

Biomarkers

HLA-A*24:02 genotypeTarget antigen expression (e.g., NY-ESO-1, WT1, MAGE-A4)

Beyond the preview

Go deeper on T-cell receptor restricted by HLA-A*24:02 (HLA-A*24:02-restricted TCR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-cell receptor restricted by HLA-A*24:02 (HLA-A*24:02-restricted TCR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call